ATHA
Athira Pharma
Athira Pharma is a clinical stage American therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer’s disease and Parkinson’s disease. The company’s main product is in very early human studies for Alzheimer’s disease as of 2019.The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer’s Drug Discovery Foundation, Dolby Family Ventures, the State of Washington’s Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.Leen Kawas currently serves as the company’s President and CEO.
Index: NASDAQ; Sector: ; Industry: ;
Marketcap: –; Volume: 190.42K; AvgVol 3m: 548.39K; Beta: –;
Cost estimate:
P/E: –; EPS: –; EPS growth quarter/prev quarter: ;
EPS growth this year: 0.70%; EPS growth past 5 years: ;
EPS ttm: -0.20;
P/S: ; P/B: ; P/Cashflow: 6.31; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: ; ROE – return on equity: ; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 4.60%; Insider Transactions:0.00%;
Institutional Ownership: ; Institutional Transactions: ;
Data update: 07/10/2020.